BIXT · Bioxytran, Inc · Insider Trading
Substantial doubt about the company's ability to continue as a going concern.
“These conditions raise substantial doubt about the Company's ability to continue as a going concern.”View the 10-Q filed Aug 14, 2026
Trades by corporate insiders — officers, directors and holders of more than 10% of the shares — disclosed to the SEC on Forms 4 and 5. Form 3 supplies initial ownership rather than a trade; Form 4 must be filed within two business days of the trade.
| Date | Insider | Role | Type | Security | Shares |
|---|---|---|---|---|---|
| 2025-11-18 | Hoberman Alan M |
Director |
Buy↑
|
common
|
210,000 |
| 2025-11-14 | Hoberman Alan M |
Director |
Award↑
|
preferred
|
38,588 |
| 2025-11-14 | CONAWAY DALE H |
Director |
Award↑
|
preferred
|
38,588 |
| 2025-11-14 | MILANOVA RADKA |
Director |
Award↑
|
preferred
|
38,588 |
| 2025-11-14 | Utter Anders |
Director |
Award↑
|
preferred
|
38,588 |
| 2025-08-12 | CONAWAY DALE H |
Director |
Award↑
|
preferred
|
10,417 |
| 2025-08-12 | Hoberman Alan M |
Director |
Award↑
|
preferred
|
10,417 |
| 2025-08-12 | MILANOVA RADKA |
Director |
Award↑
|
preferred
|
10,417 |
| 2025-01-06 | Hoberman Alan M |
Director |
Award↑
|
Preferred
|
97,535 |
| 2025-01-06 | Utter Anders |
Director |
Award↑
|
preferred
|
97,535 |
| 2025-01-06 | CONAWAY DALE H |
Director |
Award↑
|
Preferred
|
97,535 |
| 2025-01-06 | MILANOVA RADKA |
Director |
Award↑
|
Preferred
|
97,535 |
| 2024-10-25 | Utter Anders |
Director |
Award↑
|
preferred
|
20,619 |
| 2024-10-25 | Soderquist Ola |
CFO, 10% Owner |
Other↑
Filing footnotes — common (Direct)
A 1:5 exchange of Preferred Stock (earlier issued under section 16b-3) into shares of Common Stock. |
common
|
500,000 |
| 2024-10-25 | Soderquist Ola |
CFO, 10% Owner |
Other↑
Filing footnotes — preferred (Direct)
A 1:5 exchange of Preferred Stock (earlier issued under section 16b-3) into shares of Common Stock. |
preferred
|
100,000 |
| 2024-10-25 | Hoberman Alan M |
Director |
Award↑
|
preferred
|
20,619 |
| 2024-10-25 | Soderquist Ola |
CFO, 10% Owner |
Other↑
Filing footnotes — common (Direct)
A 1:5 exchange Preferred Stock (earlier issued under Section 16b-3) into shares of Common Stock. |
common
|
500,000 |
| 2024-10-25 | Soderquist Ola |
CFO, 10% Owner |
Other↑
Filing footnotes — preferred (Direct)
The shares were issued as payment for the sale of NDPD Pharma to Bioxytran |
preferred
|
10,197,611 |
| 2024-10-25 | Soderquist Ola |
CFO, 10% Owner |
Other↑
Filing footnotes — preferred (Direct)
The Shares were issued as payment for the sale of NDPD Pharma to Bioxytran |
preferred
|
10,069,396 |
| 2024-10-25 | CONAWAY DALE H |
Director |
Award↑
|
preferred
|
20,619 |
| 2024-10-25 | Sheikh Michael |
Chief Communications Officer |
Other↑
Filing footnotes — preferred (Direct)
The shares were issued as payment for the sale of NDPD Pharma to Bioxytran |
preferred
|
6,614,720 |
| 2024-10-25 | MILANOVA RADKA |
Director |
Award↑
|
preferred
|
20,619 |
| 2024-10-25 | Soderquist Ola |
CFO, 10% Owner |
Other↓
Filing footnotes — preferred (Direct)
A 1:5 exchange Preferred Stock (earlier issued under Section 16b-3) into shares of Common Stock. |
preferred
|
100,000 |
| 2024-10-24 | PLATT DAVID |
Director, CEO, 10% Owner |
Other↑
Filing footnotes — preferred (Direct)
The shares were issued as payment for the sale of NDPD to Bioxytran |
preferred
|
11,433,448 |
| 2024-10-24 | PLATT DAVID |
Director, CEO, 10% Owner |
Other↓
Filing footnotes — preferred (Indirect)
The shares were returned to treasury and cancelled The total holdings of BIXT by NDPA Pharma, an affiliate whose beneficial ownership includes David Platt, Ola Soderquist and Mike Sheikh were consolidated under indirect ownership in David Platt's filing |
preferred
(I)
|
14,085,410 |
| 2024-08-19 | PLATT DAVID |
Director, CEO, 10% Owner |
Other↑
Filing footnotes — preferred (Indirect)
The shares were acquired through conversion of debt, issued under Rule 3(a)(9). Total holdings by NDPD Pharma, Inc., an affiliate where the beneficial ownership includes the Companys officers, have been consolidated as indirect ownership in Davis Platt's filing. |
preferred
(I)
|
776,817 |
| 2024-08-19 | PLATT DAVID |
Director, CEO, 10% Owner |
Other↑
Filing footnotes — preferred (Indirect)
Total holdings by NDPD Pharma, Inc., an affiliate where the beneficial ownership includes the Companys officers, have been consolidated as indirect ownership in Davis Platt's filing. |
preferred
(I)
|
8,973,405 |
| 2024-08-19 | Utter Anders |
Director |
Other↓
Filing footnotes — common (Direct)
A 5:1 exchange by insiders shares of Common Stock (earlier issued under Section 16b-3) into shares of Convertible Preferred Stock with a conversion ratio of 1:5 shares into Common Stock. |
common
|
1,079,189 |
| 2024-08-19 | Utter Anders |
Director |
Other↑
Filing footnotes — preferred (Direct)
A 5:1 exchange by insiders shares of Common Stock (earlier issued under Section 16b-3) into shares of Convertible Preferred Stock with a conversion ratio of 1:5 shares into Common Stock. |
preferred
|
215,838 |
| 2024-08-19 | PLATT DAVID |
Director, CEO, 10% Owner |
Other↑
Filing footnotes — preferred (Direct)
A 5:1 exchange by insiders shares of Common Stock (earlier issued under Section 16b-3) into shares of Convertible Preferred Stock with a conversion ratio of 1:5 shares into Common Stock. |
preferred
|
8,605,455 |
| 2024-08-19 | Sheikh Michael |
Chief Communications Officer |
Other↓
Filing footnotes — common (Direct)
A 5:1 exchange by insiders shares of Common Stock (earlier issued under Section 16b-3) into shares of Convertible Preferred Stock with a conversion ratio of 1:5 shares into Common Stock. |
common
|
8,000,000 |
| 2024-08-19 | Hoberman Alan M |
Director |
Other↑
Filing footnotes — preferred (Direct)
A 5:1 exchange by insiders shares of Common Stock (earlier issued under Section 16b-3) into shares of Convertible Preferred Stock with a conversion ratio of 1:5 shares into Common Stock. |
preferred
|
226,678 |
| 2024-08-19 | PLATT DAVID |
Director, CEO, 10% Owner |
Other↑
Filing footnotes — preferred (Indirect)
Total holdings by Naomi Platt, spouse of David Platt. |
preferred
(I)
|
82,260 |
| 2024-08-19 | PLATT DAVID |
Director, CEO, 10% Owner |
Other↑
Filing footnotes — preferred (Indirect)
A 5:1 exchange by insiders shares of Common Stock (earlier issued under Section 16b-3) into shares of Convertible Preferred Stock with a conversion ratio of 1:5 shares into Common Stock. Total holdings by NDPD Pharma, Inc., an affiliate where the beneficial ownership includes the Companys officers, have been consolidated as indirect ownership in Davis Platt's filing. |
preferred
(I)
|
4,335,188 |
| 2024-08-19 | Soderquist Ola |
CFO, 10% Owner |
Other↑
Filing footnotes — preferred (Direct)
A 5:1 exchange by insiders shares of Common Stock (earlier issued under Section 16b-3) into shares of Convertible Preferred Stock with a conversion ratio of 1:5 shares into Common Stock. |
preferred
|
3,907,060 |
| 2024-08-19 | PLATT DAVID |
Director, CEO, 10% Owner |
Other↓
Filing footnotes — common (Direct)
A 5:1 exchange by insiders shares of Common Stock (earlier issued under Section 16b-3) into shares of Convertible Preferred Stock with a conversion ratio of 1:5 shares into Common Stock. |
common
|
43,027,274 |
| 2024-08-19 | MILANOVA RADKA |
Director |
Other↑
Filing footnotes — preferred (Direct)
A 5:1 exchange by insiders shares of Common Stock (earlier issued under Section 16b-3) into shares of Convertible Preferred Stock with a conversion ratio of 1:5 shares into Common Stock. |
preferred
|
36,529 |
| 2024-08-19 | Sheikh Michael |
Chief Communications Officer |
Other↑
Filing footnotes — preferred (Direct)
A 5:1 exchange by insiders shares of Common Stock (earlier issued under Section 16b-3) into shares of Convertible Preferred Stock with a conversion ratio of 1:5 shares into Common Stock. |
preferred
|
1,600,000 |
| 2024-08-19 | PLATT DAVID |
Director, CEO, 10% Owner |
Other↓
Filing footnotes — common (Indirect)
A 5:1 exchange by insiders shares of Common Stock (earlier issued under Section 16b-3) into shares of Convertible Preferred Stock with a conversion ratio of 1:5 shares into Common Stock. Total holdings by NDPD Pharma, Inc., an affiliate where the beneficial ownership includes the Companys officers, have been consolidated as indirect ownership in Davis Platt's filing. |
common
(I)
|
21,675,939 |
| 2024-08-19 | PLATT DAVID |
Director, CEO, 10% Owner |
Other↓
Filing footnotes — common (Indirect)
Total holdings by Naomi Platt, spouse of David Platt. |
common
(I)
|
411,300 |
| 2024-08-19 | CONAWAY DALE H |
Director |
Other↑
Filing footnotes — common (Direct)
A 5:1 exchange by insiders shares of Common Stock (earlier issued under Section 16b-3) into shares of Convertible Preferred Stock with a conversion ratio of 1:5 shares into Common Stock. |
common
|
1,060,089 |
| 2024-08-19 | MILANOVA RADKA |
Director |
Other↓
|
common
|
182,645 |
| 2024-08-19 | Soderquist Ola |
CFO, 10% Owner |
Other↓
Filing footnotes — common (Direct)
A 5:1 exchange by insiders shares of Common Stock (earlier issued under Section 16b-3) into shares of Convertible Preferred Stock with a conversion ratio of 1:5 shares into Common Stock. |
common
|
19,535,300 |
| 2024-08-19 | CONAWAY DALE H |
Director |
Other↑
Filing footnotes — preferred (Direct)
A 5:1 exchange by insiders shares of Common Stock (earlier issued under Section 16b-3) into shares of Convertible Preferred Stock with a conversion ratio of 1:5 shares into Common Stock. |
preferred
|
212,018 |
| 2024-08-19 | Hoberman Alan M |
Director |
Other↓
Filing footnotes — common (Direct)
A 5:1 exchange by insiders shares of Common Stock (earlier issued under Section 16b-3) into shares of Convertible Preferred Stock with a conversion ratio of 1:5 shares into Common Stock. |
common
|
1,133,389 |
| 2024-08-16 | CONAWAY DALE H |
Director |
Award↑
|
common
|
123,967 |
| 2024-08-16 | MILANOVA RADKA |
Director |
Award↑
|
common
|
82,645 |
| 2024-08-16 | Utter Anders |
Director |
Award↑
|
common
|
123,967 |
| 2024-08-16 | Hoberman Alan M |
Director |
Award↑
|
common
|
123,967 |
| 2024-08-15 | PLATT DAVID |
Director, CEO, 10% Owner |
Buy↑
Filing footnotes — common (Indirect)
Total holdings by NDPD Pharma, Inc., an affiliate where the beneficial ownership includes the Companys officers, have been consolidated as indirect ownership in Davis Platt's filing. |
common
(I)
|
1,592,921 |